Abscisic Acid for Insulin Resistance and Prediabetes
(ABA Trial)

Recruiting in Palo Alto (17 mi)

Overseen byBret Goodpaster, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine the effects of oral abscisic acid (ABA) on glucose metabolism in subjects with defined prediabetes.

Eligibility Criteria

This trial is for adults aged 18-65 with prediabetes, marked by fasting glucose levels between 5.6 and 7.0 mmol/L or HbA1C between 5.6% and 6.5%. Participants must be in good health, able to take oral medication, agree to lifestyle guidelines, and use effective contraception if necessary. Exclusions include recent other trials, certain physical exam findings, smoking within a year, diabetes treatment, BMI outside of the range of 19-40 kg/m2.

Inclusion Criteria

In good general health as evidenced by medical history or diagnosed with <specify condition/disease> or exhibiting <specify clinical signs or symptoms or physical/oral examination findings>

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

See 6 more

Exclusion Criteria

Treatment with another investigational drug or other intervention within 1 year.

Disqualifying findings on physical examination include cardiac murmurs, diminished pulses or the presence of bruits in the lower extremities, lower extremity thrombophlebitis, evidence of peripheral neuropathy, paresis or edema.

Pregnancy or lactation

See 6 more

Treatment Details

Interventions

Oral abscisic acid (ABA) (Dietary Supplement)
Placebo (Other)

Trial OverviewThe study tests how oral abscisic acid (ABA) affects blood sugar control and insulin sensitivity in people with prediabetes compared to a placebo group. It involves procedures like the hyperinsulinemic-euglycemic clamp technique to measure insulin sensitivity and muscle biopsies to examine tissue responses.

Participant Groups

2Treatment groups

Active Control

Placebo Group

Group I: ABA groupActive Control3 Interventions

95 ug 2x/day for 14 days

Group II: Placebo groupPlacebo Group3 Interventions

Corn Starch 300 mg for 14 days